Cardioprotection Effect of Linagliptin

Official record

Identifier

NCT07852546

Recruiting locations

country

Egypt

Interventions studied

DoxorubicinEmpaglifloz 5 mg orally once daily

Lead sponsor

Tanta University

Target enrolment

140 participants

Study type

INTERVENTIONAL

Phase

Phase 3

Status

Not yet recruiting

First posted

Oct 1, 2026

Last updated on the registry

Oct 1, 2026

Age

18 Years

Sex

FEMALE

Study contact

The official record lists a study contact. Contact details are published there and are intentionally not copied to this page.

Eligibility criteria

Reproduced verbatim from the official record. Eligibility is decided by the study team, never by this page.

Inclusion Criteria:

* 1\. Female patients aged ≥18 years. 2. Egyptian nationality. 3. Histologically confirmed breast cancer. 4. Planned treatment with a doxorubicin-containing chemotherapy regimen. 5. Expected cumulative doxorubicin dose of approximately ≥240 mg/m², or another prespecified protocol threshold.

  6\. Baseline LVEF ≥53%. 7. Adequate baseline echocardiographic assessment. 8. Baseline cardiac troponin below the laboratory's predefined exclusion threshold.

  9\. Ability to take oral medication. 10. Ability to provide written informed consent. 11. Willingness to comply with study visits, blood sampling and cardiac assessments.

Exclusion Criteria:

* 1\. Previous exposure to anthracyclines. 2. Known heart failure. 3. Baseline LVEF \<53%. 4. Previous myocardial infarction or significant coronary artery disease. 5. Significant valvular heart disease. 6. Clinically significant arrhythmia. 7. Uncontrolled hypertension. 8. Significant renal impairment according to a predefined eGFR threshold. 9. Significant hepatic impairment. 10. Active infection or another condition likely to affect troponin interpretation.

Indexed under

Breast Cancer